Myovant Sciences GmbH
Clinical Trials
68
Trial Phases
3 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (66 trials with phase data)• Click on a phase to view related trials
Study of Relugolix Alone and Relugolix Combined With Hormonal Add-Back Therapy in Healthy Premenopausal Female Participants
- First Posted Date
- 2021-07-27
- Last Posted Date
- 2021-07-27
- Lead Sponsor
- Myovant Sciences GmbH
- Target Recruit Count
- 48
- Registration Number
- NCT04978688
- Locations
- 🇺🇸
Clinical Study Site, Minneapolis, Minnesota, United States
A Study of the Effects of Erythromycin on the Pharmacokinetics of Relugolix, Estradiol, and Norethindrone in Healthy Postmenopausal Women and on the Pharmacokinetics of Relugolix in Healthy Adult Men
- Conditions
- Healthy
- Interventions
- First Posted Date
- 2021-01-19
- Last Posted Date
- 2021-09-01
- Lead Sponsor
- Myovant Sciences GmbH
- Target Recruit Count
- 43
- Registration Number
- NCT04714554
- Locations
- 🇺🇸
Clinical Pharmacology of Miami, An Evolution Research Group Portfolio Company, Hialeah, Florida, United States
Study of Relugolix With Estradiol and Norethindrone Acetate in Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids
- Conditions
- Uterine LeiomyomaUterine Fibroids
- Interventions
- Drug: Placebo for E2/NETA
- First Posted Date
- 2018-11-23
- Last Posted Date
- 2024-06-25
- Lead Sponsor
- Myovant Sciences GmbH
- Target Recruit Count
- 229
- Registration Number
- NCT03751124
- Locations
- 🇺🇸
Birmingham, Birmingham, Alabama, United States
🇺🇸Mesa, Mesa, Arizona, United States
🇺🇸Tucson, Tucson, Arizona, United States
Bone Mineral Density in Women With Uterine Fibroids or Endometriosis
- Conditions
- Uterine FibroidEndometriosis
- First Posted Date
- 2018-11-16
- Last Posted Date
- 2020-11-10
- Lead Sponsor
- Myovant Sciences GmbH
- Target Recruit Count
- 660
- Registration Number
- NCT03744507
- Locations
- 🇺🇸
Mobile, Mobile, Alabama, United States
🇺🇸Mesa, Mesa, Arizona, United States
🇺🇸Huntington Beach, Huntington Beach, California, United States
SPIRIT EXTENSION: Efficacy and Safety Extension Study of Relugolix in Women With Endometriosis-Associated Pain
- Conditions
- Endometriosis
- Interventions
- First Posted Date
- 2018-08-31
- Last Posted Date
- 2023-08-08
- Lead Sponsor
- Myovant Sciences GmbH
- Target Recruit Count
- 802
- Registration Number
- NCT03654274
- Locations
- 🇺🇸
Andalusia, Andalusia, Alabama, United States
🇺🇸Scottsdale, Scottsdale, Arizona, United States
🇺🇸Tucson, Tucson, Arizona, United States
- Prev
- 1
- 2
- 3
- Next